Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613048 | 0.95 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL8615816 | 0.85 | ALDH1A1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL11876590 | 0.79 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL7252450 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL1716936 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Valdetamide SCHEMBL1643080 | 0.77 | HTT (0.40) | ALDH1A1TSHR | |
| SCHEMBL1618591 | 0.77 | TSHR (0.38) | ALDH1A1TSHR | |
| SCHEMBL1114546 | 0.76 | — | — | |
| SCHEMBL31306888 | 0.76 | ALDH1A1 (0.31) | ALDH1A1TSHR | |
| SCHEMBL14453246 | 0.75 | TSHR (0.33) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729302-B2 | Method of producing acid halide and acid halide | FUJIFILM CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729302-B2 | Method of producing acid halide and acid halide | FUJIFILM CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120053365-A1 | METHOD OF PRODUCING ACID HALIDE AND ACID HALIDE | FUJIFILM CORPORATION (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120053365-A1 | METHOD OF PRODUCING ACID HALIDE AND ACID HALIDE | FUJIFILM CORPORATION (JP) | 2012-03-01 | — | — | US | disclosed |
| US-5827855-A | ANTICHOLESTEROL AGENTS TREATING CARDIOVASCULAR DISORDERS; ENZYME INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1998-10-27 | — | — | US | disclosed |
| EP-0605230-B1 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1997-08-27 | — | — | EP | disclosed |
| US-5451688-A | Inhibit biosynthesis of cholesterol | SANKYO COMPANY, LIMITED (JP) | 1995-09-19 | — | — | US | disclosed |
| EP-0605230-A1 | Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053365-A1 | METHOD OF PRODUCING ACID HALIDE AND ACID HALIDE | HAO2, HACL2, SHH | ALDH1A1 36/4885TSHR 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.